Speaker Profile
M.D., Ph.D., PHARMD, Director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine
Biography
Dr. Jedd D. Wolchok is a pioneering figure in cancer immunotherapy, renowned for his instrumental role in the development and approval of groundbreaking treatments for melanoma. His leadership in clinical trials led to the FDA approval of ipilimumab, the first checkpoint inhibitor immunotherapy, and the combination of nivolumab and ipilimumab, establishing new standards of care for advanced melanoma patients. Throughout his career, Dr. Wolchok has been at the forefront of translational research, focusing on novel immunotherapeutic agents and the mechanisms of immune response to cancer. His laboratory has significantly contributed to understanding the tumor microenvironment and developing strategies to overcome resistance to immunotherapy. His contributions have been recognized with numerous prestigious awards, including the His work continues to shape the future of cancer treatment, emphasizing the potential of immunotherapy to provide durable control across various cancer types.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• S. Peter Kang, Daiichi Sankyo
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Jedd D. Wolchok, Weill Cornell Medicine
Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Biomarker Decision Gates
• Chair: Levi Garraway, Roche
